JPET Assistant Professor of Medicine (Clinician-Educator)

Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Fraser, D. J.
Right arrow Articles by Halpert, J. R.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Fraser, D. J.
Right arrow Articles by Halpert, J. R.

Vol. 283, Issue 3, 1425-1432, 1997

Isolation, Heterologous Expression and Functional Characterization of a Novel Cytochrome P450 3A Enzyme from a Canine Liver cDNA Library1

David J. Fraser, René Feyereisen, Greg R. Harlow and James R. Halpert

Department of Pharmacology and Toxicology, College of Pharmacy (D.J.F., G.R.H., J.R.H.) and Department of Entomology (R.F.), University of Arizona, Tucson, Arizona

A cDNA encoding a new member of the cytochrome P450 3A subfamily, P450 3A26, has been isolated from phenobarbital-induced canine liver. The sequence encodes a protein of 503 amino acids with 33 nucleotide differences conferring 22 amino acid substitutions when compared with the previously identified canine CYP3A12 enzyme. Nine of the amino acid differences are within the substrate recognition sites (SRSs) identified for P450 family 2, with five residue substitutions clustered within SRS-6. To facilitate heterologous expression in Escherichia coli, the N-terminus of 3A26 was modified. The expressed protein comigrated with a 3A-immunoreactive protein in dog liver microsomes with a slightly greater electrophoretic mobility on sodium dodecyl sulfate-polyacrylamide gel electrophoresis than 3A12, which suggests that 3A26 corresponds to a previously noted but never characterized 3A enzyme in dogs. Functional characterization of 3A26 was undertaken with use of progesterone, testosterone and androstenedione as substrates. Assays of expressed 3A26 and 3A12 demonstrated that 3A26 displays low steroid hydroxylase activity. Identification of an additional canine 3A enzyme should increase our understanding of xenobiotic metabolism in this important animal model. These findings also suggest that 3A26 and 3A12 may be an interesting model system for the investigation of structure-function relationships involved in steroid metabolism catalyzed by members of the cytochrome P450 3A subfamily.

0022-3565/97/2833-1425$03.00/0
Copyright © 1997 by The American Society for Pharmacology and Experimental Therapeutics


This article has been cited by other articles:


Home page
 Drug Metab. Dispos.Home page
M. Mise, T. Hashizume, and S. Komuro
Characterization of Substrate Specificity of Dog CYP1A2 Using CYP1A2-Deficient and Wild-Type Dog Liver Microsomes
Drug Metab. Dispos., September 1, 2008; 36(9): 1903 - 1908.
[Abstract] [Full Text] [PDF]

Home page
 Drug Metab. Dispos.Home page
H.-Z. Bu, P. Zhao, P. Kang, W. F. Pool, E. Y. Wu, and B. V. Shetty
Evaluation of Capravirine as a CYP3A Probe Substrate: In Vitro and in Vivo Metabolism of Capravirine in Rats and Dogs
Drug Metab. Dispos., September 1, 2007; 35(9): 1593 - 1602.
[Abstract] [Full Text] [PDF]

Home page
 Drug Metab. Dispos.Home page
D. Tenmizu, K. Noguchi, H. Kamimura, H. Ohtani, and Y. Sawada
THE CANINE CYP1A2 DEFICIENCY POLYMORPHISM DRAMATICALLY AFFECTS THE PHARMACOKINETICS OF 4-CYCLOHEXYL-1-ETHYL-7-METHYLPYRIDO[2,3-D]-PYRIMIDINE-2-(1H)-ONE (YM-64227), A PHOSPHODIESTERASE TYPE 4 INHIBITOR
Drug Metab. Dispos., May 1, 2006; 34(5): 800 - 806.
[Abstract] [Full Text] [PDF]

Home page
 J. Pharmacol. Exp. Ther.Home page
P. Lu, S. B. Singh, B. A. Carr, Y. Fang, C. D. Xiang, T. H. Rushmore, A. D. Rodrigues, and M. Shou
Selective Inhibition of Dog Hepatic CYP2B11 and CYP3A12
J. Pharmacol. Exp. Ther., May 1, 2005; 313(2): 518 - 528.
[Abstract] [Full Text] [PDF]

Home page
 Drug Metab. Dispos.Home page
J. R. Kunta, S.-H. Lee, B. A. Perry, Y.-H. Lee, and P. J. Sinko
DIFFERENTIATION OF GUT AND HEPATIC FIRST-PASS LOSS OF VERAPAMIL IN INTESTINAL AND VASCULAR ACCESS-PORTED (IVAP) RABBITS
Drug Metab. Dispos., November 1, 2004; 32(11): 1293 - 1298.
[Abstract] [Full Text] [PDF]

Home page
 Drug Metab. Dispos.Home page
M. Mise, S. Yadera, M. Matsuda, T. Hashizume, S. Matsumoto, Y. Terauchi, and T. Fujii
POLYMORPHIC EXPRESSION OF CYP1A2 LEADING TO INTERINDIVIDUAL VARIABILITY IN METABOLISM OF A NOVEL BENZODIAZEPINE RECEPTOR PARTIAL INVERSE AGONIST IN DOGS
Drug Metab. Dispos., February 1, 2004; 32(2): 240 - 245.
[Abstract] [Full Text] [PDF]

Home page
 Drug Metab. Dispos.Home page
M. Shou, R. Norcross, G. Sandig, P. Lu, Y. Li, Y. Lin, Q. Mei, A. D. Rodrigues, and T. H. Rushmore
SUBSTRATE SPECIFICITY AND KINETIC PROPERTIES OF SEVEN HETEROLOGOUSLY EXPRESSED DOG CYTOCHROMES P450
Drug Metab. Dispos., September 1, 2003; 31(9): 1161 - 1169.
[Abstract] [Full Text] [PDF]

Home page
 Drug Metab. Dispos.Home page
R. A. Graham, A. Downey, D. Mudra, L. Krueger, K. Carroll, C. Chengelis, A. Madan, and A. Parkinson
In Vivo and in Vitro Induction of Cytochrome P450 Enzymes in Beagle Dogs
Drug Metab. Dispos., November 1, 2002; 30(11): 1206 - 1213.
[Abstract] [Full Text] [PDF]

Home page
 Drug Metab. Dispos.Home page
S. M. Lankford, S. A. Bai, and J. A. Goldstein
Cloning of Canine Cytochrome P450 2E1 cDNA: Identification and Characterization of Two Variant Alleles
Drug Metab. Dispos., August 1, 2000; 28(8): 981 - 986.
[Abstract] [Full Text]

Home page
 Drug Metab. Dispos.Home page
S. K. Paulson, L. Engel, B. Reitz, S. Bolten, E. G. Burton, T. J. Maziasz, B. Yan, and G. L. Schoenhard
Evidence for Polymorphism in the Canine Metabolism of the Cyclooxygenase 2 Inhibitor, Celecoxib
Drug Metab. Dispos., October 1, 1999; 27(10): 1133 - 1142.
[Abstract] [Full Text]

Home page
 Mol. Pharmacol.Home page
D. J. Fraser, Y. Q. He, G. R. Harlow, and J. R. Halpert
Use of Chimeric Enzymes and Site-Directed Mutagenesis for Identification of Three Key Residues Responsible for Differences in Steroid Hydroxylation between Canine Cytochromes P-450 3A12 and 3A26
Mol. Pharmacol., February 1, 1999; 55(2): 241 - 247.
[Abstract] [Full Text]


Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
All ASPET Journals Molecular Pharmacology Pharmacological Reviews
Molecular Interventions Drug Metabolism and Disposition

Copyright © 1997 by the American Society for Pharmacology and Experimental Therapeutics.